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Abstract 
 
 In the intestine, apoC-III delays chylomicron secretion, and causes a decrease in 
chylomicron size. Once apoC-III is in circulation, apoC-III delays triglyceride-rich 
remnants clearance by inhibiting lipoprotein lipase and liver low-density lipoprotein 
receptor. In humans, high levels of plasma apoC-III directly result in 
hypertriglyceridemia. ApoC-III is a critical cardiovascular risk factor, and humans 
expressing null mutations in apoC-III are robustly protected from cardiovascular 
disease. Because of its critical role in elevating plasma lipids and CVD risk, the factors 
that regulate apoC-III expression in the liver have been determined, and include 
glucose, insulin (through FoxO1), and dietary fat. Considerably less is known about the 
factors that regulate intestinal apoC-III. This study utilizes primary murine enteroids, 
Caco-2 cells, and dietary studies in wild-type mice to show that intestinal apoC-III 
expression does not change in response to fatty acids, glucose, or insulin 
administration, in contrast to hepatic apoC-III. Intestinal apoC-III is not sensitive to 
changes in FoxO1 expression (which is itself very low in the intestine, as is FoxO1 
target IGFBP-1), nor is intestinal apoC-III responsive to western diet, a significant 
contrast to hepatic apoC-III stimulation during western diet. These data strongly suggest 
that intestinal apoC-III is not a FoxO1 target. These data support the idea that apoC-III 
is not regulated coordinately with hepatic apoC-III, and establishes another key aspect 
of apoC-III that is unique in the intestine and different from the liver.
	   1	  
Introduction 
 
 Hyperlipidemia is central to pathophysiological development of atherosclerosis, 
the key component of coronary artery disease, a form of cardiovascular disease (CVD). 
CVD is the leading cause of death worldwide.1 Because atherosclerosis develops with 
the uptake of LDL cholesterol (LDL-C) by the vascular endothelium,2 strategies to 
prevent atherosclerosis have focused on lowering LDL-C in patients at risk for the 
disease. However, patients still have significant risk for developing CVD even when 
LDL-C is reduced to healthy levels.3,4 Therefore, strategies that aim to reduce plasma 
triglycerides are also required to eliminate hyperlipidemia and CVD risk. 
 Apolipoproteins reside on the outside of lipoproteins and can act as signaling 
molecules and ligands, and are therefore important determinants of how lipoproteins 
and the lipids inside of them are metabolized.5–7 Therefore, regulating the expression 
and abundance of specific apolipoproteins is a method by which pharmaceutical and 
dietary therapies can manage and direct lipid metabolism and moderate the risk of 
cardiovascular disease. Apolipoprotein C-III (apoC-III) is a small protein produced 
primarily by the liver and intestine.8,9 ApoC-III is secreted from these tissues on 
triglyceride-rich lipoproteins (TRLs).10–12 The presence of apoC-III on lipoproteins 
increases the resident time of these particles in circulation primarily by inhibiting uptake 
of TRLs and their remnants by the hepatic low-density lipoprotein receptor (LDLR).13–15 
In humans, plasma apoC-III levels are independently associated with both an increase 
in plasma triglycerides and CVD risk.16,17 In the liver, the apoC-III protein promotes lipid 
loading onto nascent VLDL and enhances VLDL assembly and secretion.18,19 In 
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contrast, intestinal apoC-III causes retention of unesterified dietary lipid within the 
enterocyte and a delay of triglyceride secretion into lymph.20   
  Factors that influence apoC3 gene expression in the liver have been well 
researched, however, it is unknown how apoC3 is regulated in the intestine. In the study 
presented herein, we aimed to determine if intestinal apoC3 is responsive to the same 
dietary components and metabolites as hepatic apoC3. We use primary murine 
enteroids, Caco-2 cells, and dietary studies in wild-type mice to test the effect of 
glucose, insulin, and fat on hepatic and intestinal apoC-III expression.  
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Chapter 1: Review of Literature 
 
1.1 DEVELOPMENT OF CARDIOVASCULAR DISEASE 	  
 Cardiovascular disease (CVD) is the leading cause of death in both the United 
States and globally.1 CVD is an umbrella term for a number of conditions that affect the 
heart and blood vessels, such as coronary artery disease (CAD), myocardial infarction 
(MI), and stroke. CVD tremendously affects both industrialized and unindustrialized 
countries; approximately 17.7 million or 31% of deaths worldwide occur from CVD 
related causes.1 Non-modifiable risk factors for CVD include genetic predisposition, 
age, gender, ethnicity, and socioeconomic status. However, the majority of risk factors 
for CVD, such as, hypertension, hyperlipidemia, type 2 diabetes, smoking, and stress 
are modifiable and can be improved with diet and lifestyle interventions.1,21,22  
 Hyperlipidemia is central to pathophysiological development of atherosclerosis, 
the key component of CAD. During the development and progression of atherosclerosis, 
arteries narrow and harden due to the accumulation of lipid and fibrous elements.2 This 
lipid accumulation occurs when oxidized low-density lipoprotein (LDL) particles are 
taken up by the vascular endothelium and macrophages are recruited to the site of 
injury. These lipid-laden macrophages are known as ‘foam cells.’ Foam cells become 
problematic when smooth muscle cells (SMCs) of the media migrate into the intima and, 
with extracellular matrix, form a fibrous cap that encloses a necrotic core of lipid-rich 
cells.2 These calcified arterial plaques cause stenosis that impedes oxygen-rich blood 
flow, and upon further injury to the luminal surface of the vessel, can rupture and cause 
compete occlusion resulting in myocardial infarction or stroke.  
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 Given the central role of LDL-cholesterol in development atherosclerosis, 
lowering LDL-C has been a central objective in the battle against CVD. In 1984, The 
Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT) reported that 
use of the cholesterol-lowering, bile acid sequestrant, cholestyramine, in middle-aged 
men with primary hypercholesterolemia significantly reduced plasma cholesterol which 
resulted in a significant decrease in the incidence of coronary heart disease in the 
experimental group.23 With the advent and widespread use of more potent cholesterol-
reducing medications known as HMG-CoA reductase inhibitors, or statins, which lower 
plasma cholesterol by interfering with the rate-limiting step of endogenous cholesterol 
synthesis, research studies have been able to more effectively test the hypothesis that 
reducing cholesterol significantly reduces CVD occurrence. Indeed, several meta-
analyses of randomized controlled trials have reported that statins significantly reduce 
all-cause mortality, combined fatal and non-fatal CVD and CHD events and stroke.24–27 
 Despite the impressive impact of cholesterol-lowering therapies on CVD risk, a 
troublingly large number of patients still have residual risk for CVD despite optimal LDL-
C reduction.28 For example, even one of the most important randomized control trials 
that demonstrated the success of statins in prevention of CVD-related events, The 
Scandinavian Simvastatin Survival Study (4S), reported that 19% of people in the 
simvastatin-treated group had one or more major coronary events in the 5.5 year follow-
up period.29 These data and others like them, suggest significant residual risk even for 
patients being treated with cholesterol-lowering drugs. Strategies that target the 
reduction of LDL-C as a means to reduce morbidity and mortality from CVD-related 
causes are not wholly effective, and hence, investigation into additional methods to 
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eliminate CVD occurrence is warranted.  
1.2 ANOTHER TARGET FOR REDUCING CVD RISK 
 
 Elevated plasma triglyceride level is the other detrimental, component of 
hyperlipidemia. Nearly half a century ago JL Goldstein, AG Motulsky et al. asserted that 
hypertriglyceridemia might be as significant a risk factor for coronary atherosclerosis as 
hypercholesterolemia.3 In their study of 500 fasting survivors 3 months post myocardial 
infarction, they reported that hypertriglyceridemia with (7.8%) or without (15.6%) 
accompanying elevation in cholesterol levels was three times more common in 
survivors than a high cholesterol level alone (7.6%).3 This incidence of hyperlipidemia 
without hypercholesterolemia may account for the residual risk for CVD despite 
cholesterol-lowering interventions, and underlies the importance of studying TAG and 
the metabolism of triglyceride-rich lipoproteins that carry TAG throughout the body. 
Indeed, hypertriglyceridemia has since emerged as an independent risk factor for CVD. 
Two separate prospective studies, the Cholesterol and Recurrent Events (CARE) trial in 
the United States, and The Copenhagen City Heart Study in Denmark, reported that 
non-fasting plasma triglyceride level is a strong and independent predictor of future 
myocardial infarction, ischemic heart disease, and death in both normo- and hyper- 
cholesterolemic men and women. 4,30 
 Apolipoproteins, with the exception of apo-B which provides more of a structural 
framework for the particle, are proteins that reside on the outside of lipoproteins. 
Lipoproteins like chylomicrons, VLDL, LDL, IDL, and HDL, carry lipids and cholesterol 
through the aqueous environment of the blood under their phospholipid coat.7 
Apolipoproteins can act as signaling molecules and ligands, and their placement on the 
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outside of lipoproteins makes them important determinants of how lipoproteins and their 
lipid cargo is metabolized.5–7 
Apolipoprotein C-III links hypertriglyceridemia with increased CVD risk. ApoC-III 
is a small, 79 amino acid protein produced predominantly by the liver and small 
intestine, and is exported on the lipoproteins from these organs: VLDL and 
chylomicrons, respectively.8,9 Apo C-III is a key determinant in how, and how quickly, 
triglyceride-rich lipoproteins are exported into plasma and catabolized by peripheral 
tissues. The protein is exchangeable in plasma, and therefore can migrate amongst 
different types and species of lipoproteins.31 The presence of apoC-III on lipoprotein 
particles delays their catabolism and prolongs the period of time lipoproteins remain in 
circulation.32 Hence, not surprisingly, plasma abundance of apoC-III directly correlates 
with plasma triglyceride levels.33 Additionally, a high concentration of apoC-III on VLDL 
and LDL, independent of plasma triglyceride level, is a measure of coronary heart 
disease risk.34 Given the increased risk of CVD incidence and adverse cardiovascular 
events that accompanies elevated plasma triglycerides, and the atherogenicity of apoC-
III itself, the ability to strategically manipulate expression of apoC-III is a promising tactic 
to combat CVD occurrence.    
1.3 FUNCTIONS OF APOC-III 
 
Effect of apoC-III on circulating TAG levels 
The level of apoC-III expression directly correlates to triglyceride levels in both 
rodent models and humans. During the development of a human apoC3 transgenic 
mouse model, Breslow et al. found that mice lines with 100 copies of the gene were 
severely hypertriglyceridemic, while other lines with only a one to two copies of the gene 
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produced less apoC-III protein and had only mildly elevated triglyceride levels.35 This 
gene dose effect is similarly apparent in humans; humans heterozygous for a defective 
apoC3 allele, such as the Lancaster Amish who are carriers of the null R19X mutation in 
the apoC3 gene, produce half as much apoC-III as those without the mutation.36 These 
heterozygous carriers of the mutant gene also have a corresponding decrease in 
plasma triglycerides and coronary artery calcification, which is a marker of subclincal 
atherosclerosis.36 Additionally, other genome-wide association studies (GWAS) have 
uncovered several distinct populations with rare mutations that affect ApoC3 function. 
These loss-of-function mutations in ApoC3 are associated with hypotriglyceridemia and 
confer nearly complete cardioprotection. 37–40 
 
Interference with TRL lipolysis and clearance 
 Several mechanisms by which apoC-III elevates plasma TAG have been 
established. In 1972, Brown and Baginsky first described apoC-III as an inhibitor of 
lipoprotein lipase (LPL),9,41 which reduced the lipolysis and unloading of lipid into 
peripheral tissues, therefore keeping more TAG retained in large lipoproteins longer. 
Yet a small clinical study that tested the effect of the apoC-III specific antisense 
oligonucleotide (ASO), volanesorsen, in patients with a genetic LPL deficiency and 
resultant chylomicronemia, resulted in significant reductions of plasma TAG in these 
patients.42 These patients do not have functioning LPL but their plasma TAG levels 
were still reduced when apoC-III expression was ablated, suggesting that the inhibition 
of LPL by apoC-III is not the mechanism, or at least not the central mechanism, by 
which apoC-III raises circulating triglyceride levels. This trial indicates that apoC-III 
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interferes with another mechanism by which lipid is cleared from plasma, independent 
of LPL.15,42  
 Likely the most significant mechanism by which apoC-III increases plasma TAG, 
is through its interference with hepatic receptors that clear TRLs and their remnants 
from circulation.15 Gordts and Esko et al.15 also used the ApoC-III ASO volanesorsen, 
which binds apoC-III mRNA and targets it for degradation, to reduce apoC-III levels in 
several distinct mutant mouse lines, including: low-density lipoprotein receptor (LDLR) 
knockouts, LDLR-related protein 1 (LRP1) knockouts, and heparan sulfate proteoglycan 
receptors (HSPGs) knockout mice, as well as additional sets of mice who were double 
knockouts for a pair of receptors. The results of their experiments show that apoC-III 
ASO treatment lowered plasma TAG in mice lacking hepatic HSPG receptors, LDLR, or 
LRP1. The drug also reduced TAG in animals with combined deletion of the genes 
encoding HSPG receptors and LDLRs or LRP1. However, apoC-III ASO treatment did 
not reduce triglycerides in mice who were knockouts of both	  LDLR and LRP1, 
suggesting that apoC-III primarily elevated plasma triglyceride levels by impeding 
hepatic TRL clearance via these receptors.15 
 There is also evidence that apoC-III inhibits hepatic TRL uptake by interfering 
with or displacing apoE, a major ligand by which liver receptors clear lipoproteins. 
Hypertriglyceridemic, human apoC-III transgenic mice accumulate triglyceride-rich, 
VLDL-like particles carrying abundant apoC-III and lacking apoE.14 Furthermore, human 
lipoprotein kinetic studies conducted by the Zheng et al. have shown that patients with 
hypertriglyceridemia produce 3-times more VLDL without apoE but with apoC-III, than 
do normolipidemic controls.43 Additionally, the apoC-III-containing apoB lipoproteins 
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devoid of apoE were removed significantly more slowly from circulation than those with 
both apo C and E.43 
 
Promotion of VLDL assembly and secretion 
 In rat hepatoma McA-RH7777 cells transfected with human apoC-III and cultured 
in lipid-rich conditions, apoC-III increases VLDL-TAG secretion in a gene dose-
dependent manner.19 ApoC-III seems to promote lipid-loading into VLDL particles in the 
liver by functioning in conjunction with microsomal triglyceride transfer protein (MTP).44 
Transfection of human apoC-III into these hepatoma cells significantly increased the 
mRNA expression and activity of MTP.18 In the initial stages of VLDL synthesis, 
lipidation of hepatic apoB begins immediately as the apoB protein is translated. 45 
However, MTP is crucial for the continued lipidation of the nascent lipoprotein and is 
necessary to avoid degradation of lipid-poor apoB.46 MTP is also required for later 
stages of lipid loading, in the recruitment of triglyceride into the endoplasmic reticulum 
and Golgi compartments for VLDL assembly.44,47 Labeling of apoC-III protein with 
[35S]methionine/cysteine in the same experiment using human apoC-III- expressing 
McA-RH7777 cells, showed that the majority of apoC-III was distributed within TAG-rich 
microsomal lumen fractions.19 This data may suggest that apoC-III works in conjunction 
with MTP to partition TAG substrate into the endoplasmic reticulum and Golgi for VLDL 
assembly.19,44 In support of the idea that apoC-III promotes VLDL lipid loading and 
secretion, is the finding that subjects with missense mutations in the ApoC3 gene that 
code for its lipid-binding domain have unusually low plasma triglycerides.36,48,49  
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Atherogenicity of apoC-III 
 ApoC-III is a potent regulator of plasma triglyceride levels, but research has also 
demonstrated that apoC-III is proatherogenic aside from its role in elevating triglyceride 
concentration. In a prospective study of 2 populations: the female participants in the 
Nurses’ Health Study (NHS) and the male participants in the Health Professionals 
Follow-up Study (HPFS), Mendivil & Sacks (2011)50 sought to determine if increased 
concentrations of VLDL and LDL with apoC-III is associated with increased CVD risk 
versus VLDL and LDL devoid of apoC-III. The subjects in the two populations were free 
of CVD at the start of the study. Researchers found that concentrations of LDL with 
apoC-III positively correlate with risk of coronary heart disease in multivariable analysis 
that included the ratio of total cholesterol HDL cholesterol, LDL cholesterol, apoB, 
triglycerides, or HDL cholesterol and other risk factors.50 While several other studies 
have implicated increased apoC-III concentrations with the development and 
progression of atherosclerosis 51–54 and the incidence of adverse cardiovascular events 
associated with CVD,34,50,55,56 the molecular mechanisms by which apoC-III functions to 
promote atherosclerosis are still poorly understood.  
 
Role of apoC-III in the intestine  
 Research has focused on the role of apoC-III in the liver and its role on plasma 
lipoproteins. Comparatively, little is known about the role of apoC-III in the small 
intestine. ApoC-III protein is present on chylomicrons secreted from the intestine. ApoC-
III mRNA expression in the duodenum is approximately 30% of the amount produced in 
the liver, with the most proximal section of the small intestine producing the most and 
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the ileum the least.20 Human apoC-III transgenic mice express about 5 times more 
apoC-III mRNA with the same tissue distribution of apoC-III as wild-type mice, hence 
this model can also be used to study apoC-III overexpression and its consequences in 
the intestine.20  
 Emerging evidence suggests that the role of apoC-III in intestine differs 
significantly from that in the liver. Contrary to apoC-III’s function of increasing VLDL 
assembly and secretion in the liver, 19 intestinal apoC-III appears to inhibit TAG 
secretion into lymphatic circulation. Kohan and Wang20 reported that human apoC3 
transgenic mice infused intraduodenally with radiolabeled lipid demonstrated delayed 
uptake of the lipid from the intestinal lumen, impaired esterification of FFA and MAG into 
TAG, and decreased secretion of lipid from the intestinal enterocytes into lymph.20 In 
line with this finding, intestinal organoids prepared from intestinal stem cells from human 
apoC-III transgenic mice secrete smaller, less dense chylomicrons with less TAG. 
These data suggest that the function of intestinal apoC-III and the physiological 
outcome of expressing intestinal apoC-III, are both entirely opposite to their function in 
the liver.  
1.4 REGULATION OF APOC3 IN THE LIVER & INTESTINE 
 
 Scarce data exist regarding what factors regulate apoC3 gene expression in the 
intestine, but a number of nutrients and metabolites have been shown to regulate 
hepatic apoC3 via action on various transcription factors51. ApoC-III may contribute to 
the development of diabetic dyslipidemia in the insulin resistant state because its 
expression in the liver is upregulated by glucose and downregulated by insulin.57 In 
primary rat hepatocytes and immortalized human hepatocytes, glucose increases apoC-
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III transcription by activating transcription factors HNF-4α and ChREBP, which bind E-
boxes found in the proximal C3P footprint in the apoC3 promoter.57 FXR and PPARα 
agonists decrease hepatic expression of apoC3 because FXR and PPARα can displace 
HNF-4α from its location in the apoC3 enhancer region or the CP3 footprint.57,58 
 Insulin’s impact on hepatic apoC3 expression is primarily attributed to the 
transcription factor Forkhead box O1 (FoxO1). When active, FoxO1 binds to the apoC3 
promoter and stimulates transcription.59 FoxO1 is deactivated by insulin via signaling 
through the insulin receptor substrate (IRS) which causes phosphorylation of Foxo1 
through the PI3K/Akt pathway and consequent nuclear exclusion.60,61 Streptozotocin-
treated mice, which model an insulin deficient diabetic state, have an approximately 1.5 
fold increase in hepatic apoC-III mRNA levels, accompanied by elevated plasma 
glucose and triglycerides.62 Hepatic apoC-III mRNA expression can be reduced by 
nearly 60%, and glucose and triglyceride levels normalized, when the animals are 
treated with insulin.62 Similarly, HepG2 cells transfected with an apoC-III reporter 
construct demonstrate a dose-dependent downregulation of apoC-III transcription in 
response to insulin.62 In primary rat hepatocytes transfected with FoxO1 cDNA by 
adenovirus, FoxO1 stimulates apoC-III mRNA expression and the hepatocytes exhibit a 
dose-responsive decrease in apoC-III transcription upon treatment with insulin.59 
Deletion or mutation of the FoxO1 binding site in the apoC-III promoter ablates this 
response to insulin and the corresponding FoxO1-mediated stimulation of apoC-III gene 
expression.59  
 FoxO1 has also been implicated in the regulation of apoC-III gene expression in 
the intestine, but only in one study. In the same study mentioned above, by Altomonte 
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and Dong et al,59 in which researchers delivered FoxO1 cDNA to primary rat 
hepatocytes, they also conducted an experiment on Caco-2 cells overexpressing 
constitutively active FoxO1. Like the hepatocytes, Caco-2 cells overexpressing FoxO1 
also produced more apoC-III mRNA and this expression was attenuated with insulin 
treatment. 59 However, the experiment did not examine the effect of insulin on Caco-2 
cells that were not vector-transduced --those with only basal, physiological levels of 
FoxO1. Hence, the experiment did not determine if FoxO1 is a central regulator of 
apoC-III expression in the intestine. 
 Hepatic apoC-III gene expression appears to be moderated in part by the action 
of PPARα on FoxO1. Fibrates, which are PPARα agonists, are known to downregulate 
the expression of apoC-III in the liver and to reduce plasma concentration of apoC-III in 
both animal and human studies.63 PPARα inhibits FoxO1 binding to the insulin-
responsive element in the apoC3 gene.64 Long chain, n-3 polyunsaturated fatty acids 
(PUFAs) like docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), which are 
found in fish and algal oils, are ligands that trigger PPARα activation.65–67 In the liver, 
DHA suppresses the expression of FoxO1 and its target genes which include MTP, 
glucose-6-phosphatase, insulin-like growth factor binding-protein 1 (IGFBP1) and apoC-
III.68 Hence, this activation of PPARα, and subsequent deactivation of FoxO1 which 
results in less apoC-III expression in the liver, may contribute to the hypolipedemic 
effect of fish oil supplementation in humans.69–73  
 
1.5 CONCLUSION 
 
 ApoC-III is a potent modulator of plasma triglyceride levels and abundance of this 
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apoprotein in human plasma is proatherogenic.16,34,74 Given the widespread impact of 
CVD worldwide, new and effective therapies to reduce CVD risk are necessary. ApoC-
III promotes hypertriglyceridemia by promoting VLDL assembly in the liver and 
decreasing clearance of TRLs from circulation.15,19 Glucose, insulin, and dietary n-3 
fatty acids have an impact on hepatic apoC-III expression.57,59,68 However, considerably 
less is known about the role and regulation of apoC-III in the intestine. Interestingly, 
what is known about the function of intestinal apoC-III is paradoxical to its role in the 
liver; intestinal apoC-III delays secretion of chylomicrons and their TAG cargo.20,75 
ApoC-III can be a valuable target in reducing CVD risk, however given the differences 
between hepatic and intestinal apoC-III, more research regarding the tissue-specific 
function of this apoprotein is warranted. 
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Chapter 2: Key differences between apoC-III regulation and expression in 
intestine and liver. 
 
 
This chapter is presented in its previously published format. 
 
West G, Rodia C, Johnson Z, Li D, Dong H, Kohan AB. Key differences between apoC-
III regulation and expression in intestine and liver. BBRC. (2017) 
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INTRODUCTION 
 
 Apolipoprotein C-III (apoC-III) is expressed in both liver and the intestine, and is 
secreted from these tissues on triglyceride-rich lipoproteins (TRLs)10–12. ApoC-III was 
first established as an inhibitor of lipoprotein lipase (LPL), and it has been more recently 
established that the most robust role of apoC-III is likely its inhibition of hepatic low-
density lipoprotein receptor (LDLR)13–15. These inhibitory actions of apoC-III increase 
the plasma residence time of TRLs and their remnants. In humans, plasma apoC-III 
levels are independently associated with both an increase in plasma triglycerides and 
CVD risk 16,17.  
 Elevated plasma triglycerides are an independent risk factor for cardiovascular 
disease (CVD), the leading cause of mortality in the United States. The importance of 
apoC-III in human CVD incidence has been well-established: in patients with the R19X 
null mutation in apoC-III, CVD incidence is significantly reduced, whereas in patients 
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with elevations in plasma apoC-III, CVD incidence in robustly increased 34,36–38,74,76.  
 We have recently established an intestinal role for apoC-III. We find that 
overexpression of apoC-III results in a delay in dietary lipid absorption and causes the 
secretion of smaller chylomicrons 20,75. This is paradoxical to both the triglyceride-raising 
role apoC-III plays in the plasma, and cell culture data suggesting that intracellular 
apoC-III promotes the synthesis and secretion of larger, more triglyceride-rich VLDL 
from the liver 18,48.  
 Research on the mechanisms that control apoC-III gene expression has focused 
on hepatic apoC-III. In primary rat hepatocytes, glucose upregulates apoC-III 
transcription by activating transcription factors HNF-4α and ChREBP, which bind E-
boxes found in the proximal C3P footprint in the apoC-III promoter 57. Conversely, 
insulin down-regulates hepatic apoC-III through phosphorylation and nuclear exclusion 
of the transcription factor Forkhead box O1 (FoxO1)77. Furthermore, hepatic apoC-III 
mRNA is significantly elevated in mice with streptozotocin-induced insulin deficiency 62. 
In liver, polyunsaturated fatty acids inhibit FoxO1 expression and its target genes in 
liver, including apoC-III 68. 
 While the regulation of hepatic apoC-III gene expression has been well studied, 
the factors that regulate apoC-III in the intestine are still largely unknown. In Caco-2 
cells overexpressing constitutively active FoxO1, apoC-III mRNA is significantly 
increased 59. However, little is known about the role of physiological levels of FoxO1 in 
apoC-III regulation in the intestine. Unlike hepatic apoC-III, which is inhibited by long 
chain polyunsaturated fatty acids 68, it is unknown how intestinal apoC-III expression 
responds to dietary fat.  
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 Since we have previously established that the role of apoC-III in the intestine 
differs significantly from that in the liver, the purpose of this study is to establish the in 
vivo regulation of intestinal apoC-III. In this work, we establish that intestinal apoC-III 
expression is not responsive to dietary fat or glucose, and in primary murine enteroids 
and Caco-2 cells, apoC-III expression is not inhibited by insulin. We also show that in 
contrast to the liver, intestinal FoxO1 expression is very low and apoC-III is not 
regulated coordinately with FoxO1 target genes in the intestine. Finally, intestinal apoC-
III expression does not change in response to a western diet challenge, whereas we 
confirm previous studies showing that hepatic apoC-III expression is stimulated by 
western diet. Our findings support the notion that though the liver and intestine share 
TRL synthesis and secretion, they do not share identical regulatory pathways for 
proteins that are involved TRL synthesis and secretion. 
METHODS 
 
Animals. Male and female C57Bl/6J mice (Jackson Laboratories, Bar Harbor, ME), 8-
12 weeks old, were housed 3-4 per cage in a temperature-controlled (23 ±1°C) vivarium 
on a 12-h light-dark cycle. Mice received free access to water, and were maintained on 
either standard rodent chow (Teklad global cat.#2918) or western diet (42% kcal from 
fat, 0.2% cholesterol by weight) from Envigo TD.88137, for 12 weeks. Animals were 
sacrificed under isoflurane anesthesia following an overnight fast. For gavage studies, 
mice continued on chow diet and were gavaged at the same time daily for one week 
with saline, corn oil (60µL), or corn oil (60µL) with glucose (135µL of 5M glucose). Each 
gavage was made isovolumetric (195µL) using saline. Mice were fasted overnight on 
the last day before they were sacrificed. The next morning, plasma, liver, and small 
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intestine were collected, flash frozen in liquid nitrogen, and stored at -80°C until 
analysis. All animal procedures were performed in accordance with the University of 
Connecticut Internal Animal Care and Use Committee and in compliance with the 
National Institutes of Health Guide for the Care and Use of Laboratory Animals. 
 
Caco-2 cells. Caco-2 cells were used for experiments at 17d post-confluence. As 
described by Nauli et al. 78, this protocol produces the most abundant apoB-lipoproteins. 
Cells were kept at 37°C with 5% CO2 in Eagle’s Minimum Essential Medium with L-
Glutamine (Corning Cellgro #10-010-CM), 10% Fetal Bovine Serum (FBS), 1% L-
glutamine, penicillin/streptomycin, sodium pyruvate, non-essential amino acids, and 1.5 
g/L sodium bicarbonate. For experiments, cells were serum starved overnight prior to 
treatments. To measure the effect of varying concentrations of glucose and insulin, we 
incubated cells in low glucose DMEM (1g/L glucose) and high glucose DMEM (4.5g/L) 
with and without human insulin (final concentration 80nM, Sigma, St. Louis, MO. cat# 
I9278). Cells were treated with 2mL of treatment media in each well for 24 hours. After 
24 hours, media was collected and cells were washed with ice cold 10% phosphate-
buffered saline (PBS). Cells were incubated in fatty acid growth medium for 4 hours 
before they were washed with ice cold 10% PBS (phosphate-buffered saline). Fresh 
media was added to each well and plates were incubated for 24 hours before protein 
and RNA analysis.  
 
Enteroid Culture. We isolated intestinal stem cells (ISCs) from crypts as described 
previously 75,79. Primary crypts were isolated from WT mice, age 8-12 weeks. Crypts 
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were placed in Matrigel; following 30min polymerization, crypts were treated with 500µl 
of enteroid medium (Advanced DMEM/F12 (12634- 010; Life Technologies, Carlsbad, 
CA, USA) with 2mM L-Glutamine, 10mM HEPES, 100U/mL penicillin/100µg/mL 
streptomycin and 1× N2 and 1× B27 supplements,lus 1µL of R-spondin 1 (250µg/mL), 
1µL of Noggin (50µg/mL) and 0.25µL of EGF (100µg/mL). Media was replaced every 3 
days. For treatment with lipid, mature enteroids were dissociated from Matrigel by 
washing with ice cold DPBS, followed by a 150x g spin for 10 min. After removing the 
supernatant, the intact enteroids were then placed in 1ml of treatment media containing 
400µM OA: BSA or BSA alone, or enteroid growth media containing glucose, or 
enteroid growth media containing insulin; all media contained Rho-kinase inhibitor. The 
enteroids were very gently opened by pipetting up and down with a p1000 pipette, 
followed by incubation with the lids open in a 37° 5% CO2 incubator for 2 hours. After 2 
hours, the enteroids were centrifuged at 150 x g for 10 minutes and the supernatant 
collected. Following an additional wash and centrifuge with 1ml of DPBS (which was 
added to the media samples), the enteroids were resuspended in 1ml of enteroid growth 
media and placed back in the incubator for 6 hours, with the lid to their tubes left open 
for gas exchange. The media and cell pellet were then collected via centrifugation at 
150 x g for 10 minutes.  
 
Preparation of BSA-bound FFA. To test the effect of dietary fatty acids on apoC-III 
expression, we treated the enteroids and Caco-2 cells with BSA-bound FFA. Oleic acid 
(Nu-Check Prep) was prepared as 4mM stock solutions in complex with fatty acid-free 
bovine serum albumin (BSA) at a 1:4 molar ratio and the stock contained butylated-
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hydroxytoluene 0.1% (19). Cells not receiving the 400µM OA: BSA complex were 
treated with an equivalent amount of BSA.  
 
Immunofluorescence.  Enteroids were grown in chamber glass wells and fixed with 
4% PFA in PBS for 30 min, followed by 50mM NH4Cl in PBS for 30min to quench 
autoflorescence. They were washed 5X with PBS, followed by 0.5% Triton X-100 in 
PBS for 30min, and then were blocked in 5%BSA in PBST overnight at 4°C. Fixed 
enteroids were incubated with primary antibody against apoB (1:100, Abcam #ab20737) 
for 3 days at 4°C. After 5 washes with PBS, samples were incubated with secondary 
Alexa 488 (1:500, Abcam #ab150065) overnight at 4°C. Enteriod were also stained with 
nuclei stain Hoechst 33342 (10µg/ml in PBST). Images were captured by confocal 
microscopy use NiKon A1R (20X and 60X water objective lens). 
 
Gene Expression via RT-qPCR. RNA was isolated from washed cells (Caco-2 and 
enteroids) and isolated tissues (gavage and western diet mice) according to Trizol 
product instructions. RNA pellets were dissolved in nuclease-free dH2O before 
concentration was determined using a BioTek Epoch spectrophotometer. cDNA was 
synthesized using 2 µg of RNA in a iScript cDNA synthesis kit (BioRad, #1708890). 
Quantitative real-time polymerase chain reaction (PCR) was conducted using the CFX 
Connect real time system (BioRad) and iTaq SYBR® Green Supermix (Bio-Rad). 
Human RPLPO was used as the reference gene in the Caco-2 studies. Mouse 
cyclophilin was used as the reference gene in dietary studies. Gene expression was 
calculated using the comparative threshold cycle method.  
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Plasma lipid and glucose analysis. To measure plasma lipids, we used the Randox 
(catalog # TR210) triglyceride assay and total cholesterol assay (catalog # CH200), in 
mice that had been fasted overnight (6pm-6am). Plasma glucose was also measured in 
the fasted state, using liquid glucose oxidase assay by Pointe Scientific, Inc (Canton, MI 
G7521-120). 
 
Statistics. All data are presented as the mean ± the SEM. Statistics were performed 
using GraphPad Prism (version 6.0). The differences were analyzed by Student’s t-test. 
Analyses of more than 1 experimental group, compared to control tissue, were analyzed 
by one-way ANOVA. Differences were considered significant at P < 0.05.  
 
RESULTS 
In murine intestinal enteroids, apoC-III is not regulated by glucose, insulin, or 
fatty acid.   
 Although previous studies have determined that insulin 77, glucose 57, and fatty 
acids 68 regulate apoC-III expression in the liver, little is known about intestinal apoC-III 
regulation. To determine how intestinal apoC-III is regulated, we utilized a primary 
intestinal enteroid culture system. Primary enteroids are derived from WT mouse 
duodenal and jejunal crypt stem cells, and we have previously established that this 
tissue culture system significantly improves upon Caco-2 cells as a model for dietary fat 
absorption and chylomicron secretion 75. In Fig. 1A we show the 3-dimensional 
architecture of mature primary enteroids, which apoB-positive cells surrounding a 
central lumen (reflecting the in vivo architecture of the intestine). Because hepatic 
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apoC-III is regulated by both glucose and insulin, we tested the hypothesis that these 
conditions may also regulate intestinal apoC-III. Treatment of enteroids with glucose or 
insulin did not alter intestinal apoC-III expression in the enteroids (Fig. 1B, 1C). Since 
apoC-III is secreted from enterocytes on chylomicrons (a process that is stimulated by 
dietary fat), we hypothesized that intestinal apoC-III would also be responsive to dietary 
fatty acids4. After incubation of primary enteroids with oleic acid (Fig. 1D), we 
determined that intestinal apoC-III mRNA expression is not stimulated by this fatty acid. 
We confirmed these results in Caco-2 cells, since it has been previously shown that 
Caco-2 cells transfected with FoxO1, have decreased apoC-III expression in response 
to increasing insulin concentrations 77. As in our enteroid culture studies, incubation with 
glucose, insulin, or oleic acid did not alter apoC-III expression in Caco-2 cells. Taken 
together, these results indicate in both primary intestinal enteroids and Caco-2 cells, 
apoC-III mRNA is uniquely non-responsive to changes in glucose, insulin, or fatty acids. 
This contrasts with the well-established regulation of hepatic apoC-III by these factors.     
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Fig. 1: ApoC-III mRNA expression in primary murine enteroids or Caco-2 
cells is not affected by treatment with glucose, insulin, or oleic acid. (A) 
Primary duodenal murine enteroids were cultured for 10 days until they reach 
maturity with cells arranged around a central lumen, and a basolateral face 
towards the media. Enteroids were fixed and stained with Hoechst stain (blue: 
nuclei) and anti-apoB (green) to visualize the 3D architecture of the enteroid 
culture. Enteroid and Caco-2 cell (cultured for 17d post-confluence) apoC-III 
mRNA expression in response to (B) glucose, (C) insulin, (D) BSA bound oleic 
acid. Bars represent mean apoC-III expression ±SEM, n=3-7. 	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FoxO1 expression is low in the intestine  
 Since we saw no changes in intestinal apoC-III expression in response to 
glucose were observed, insulin, and fatty acid, we decided to investigate whether 
intestinal apoC-III is a target of FoxO1 inhibition in the intestine. We find that in 
comparison to hepatic FoxO1 mRNA expression, its expression in duodenal enteroids is 
low to undetectable (Fig 2A). We also find that treating primary enteroids with insulin, in 
the presence of either low or high glucose, does not change FoxO1 mRNA expression 
(Fig. 2B).  
 
 
 
 
 
 
 
Fig. 2: FoxO1 mRNA expression in murine enteroids. (A) FoxO1 mRNA 
expression in WT mouse liver (fasted) and mature murine duodenal enteroids 
FOXO-1, normalized to cyclophilin. (B) FoxO1 mRNA expression in mature 
murine duodenal enteroids when treated for 6-h with insulin, in both low glucose 
(5.5 mM) and high glucose (25 mM) media. Bars represent mean apoC-III 
expression ±SEM, n=3-5. 
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In vivo, intestinal apoC-III mRNA expression is not regulated in response to 
gavaged lipid and glucose. 
 
 To further explore the differences in acute hepatic and intestinal apoC-III 
regulation in response to diet, we took an in vivo approach. We gavaged WT mice daily 
for one week with either saline, corn oil, or corn oil l plus glucose. After the treatment 
period, hepatic apoC-III expression increased with both the corn oil and corn oil + 
glucose treatment, confirming that hepatic apoC-III expression is regulated by these 
dietary nutrients (Figure 3A). In contrast, intestinal apoC-III expression did not change 
under any treatment condition, further corroborating the cell culture findings (Figure 3A). 
Since FoxO1 is regulated by both expression, phosphorylation, and nuclear exclusion, 
we measured the expression of canonical FoxO1 target gene, insulin-like growth factor 
binding protein 1 (IGFBP-1), in response to the gavaged nutrients (Fig. 3B). We find that 
in the liver, corn oil plus glucose robustly stimulate IGFBP-1, in parallel with apoC-III 
expression (and suggesting that FoxO1 is active under these conditions). In contrast, 
IGFBP-1 is non-detectable in the intestine in response to gavage.  
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Western diet stimulates hepatic apoC-III expression but does not alter intestinal 
apoC-III expression. 
 
 Western diet is known to increase plasma triglycerides, and the expression of 
genes in the liver that increase CVD risk. It is unknown to what extent the increase in 
plasma triglycerides are due to an increase in intestinal or hepatic apoC-III. We 
challenged WT mice for 12 weeks with western diet, consisting of 42% calories from 
butterfat and 0.2% total cholesterol, and compared these to mice provided standard 
chow diet. In response to western diet, mice have a significant increase in body weight 
compared to chow-fed controls (Fig. 4A). As expected, WT mice on the western diet 
had an approximately 2-fold increase in plasma TAG (53.15mg/dL versus 24.37mg/dL; 
p=0.01. Fig. 5B) and an approximately 3-fold increase in plasma cholesterol (230mg/dL 
Fig 3. Duodenal mRNA expression of FoxO1 target genes, apoC-III and 
IGFBP-1, are not changed after a week-long daily gavage. (A) ApoC-III mRNA 
expression in liver or intestine in response to 1 week of daily gavages of 
isovolumetric saline, corn oil (60µL), or corn oil (60µL) with glucose (135µL of 5M 
glucose). (B) IGFBP-1 mRNA expression in liver or intestine of gavaged mice. Bars 
represent ±SEM of normalized mRNA expression, *P<0.05 versus saline, not 
detectable (nd), n=3-4 WT mice per gavage group. 	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versus 77mg/dL; p=0.01. Fig.4C). Plasma glucose was not significantly increased in 
response to the western diet (Fig. 4D). Suggesting that the mice do not lose insulin-
tolerance after the 12 week western diet.  
 
  
 In response to the western diet, hepatic apoC-III expression is significantly higher 
compared to chow-fed controls (Fig. 5A), and both hepatic FoxO1 mRNA and its 
canonical target gene, IGFBP1, are also increased in parallel to apoC-III (Fig. 5B, 5C). 
Fig. 4: A 12 week western type diet alters plasma lipids and increases body 
weight compared to a chow diet. (A) Fasting plasma triglycerides in chow and 
WTD-fed mice. (B) Terminal body weights in grams. (C) Fasting plasma total 
cholesterol. (D) Fasting blood glucose blood glucose levels after the diet concluded.  
Data represent mean ± SEM. *P<0.05, ***P<0.001, n=5 per diet. 
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In contrast to these hepatic changes, western diet did not alter the expression of 
intestinal apoC-III (Fig. 5D). Interestingly, intestinal FoxO1 expression was decreased in 
the intestine and IGFBP1 is not changed (Fig. 5E, 5F). These data confirm that apoC-III 
is not regulated in the intestine, as it is in the liver, and strongly suggests that FoxO1 is 
not responsible for intestinal apoC-III mRNA regulation, in contrast to its importance in 
regulating apoC-III in the liver.  
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Fig. 5: Western diet increases hepatic but not intestinal apoC-III. Hepatic 
mRNA expression of (A) apoC-III, (B) FoxO1 and (C) IGFBP-1 expression in chow-
fed versus WTD-fed mice. Intestinal expression of (D) apoC-III, (E) FoxO1 and (F) 
IGFBP-1. Bars represent ±SEM of normalized mRNA expression, *P<0.05 versus 
chow-fed, n=5/diet. 	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DISCUSSION 
 
 Hepatic apoC-III regulation has been studied at length because of its importance 
in triglyceride homeostasis and ultimately its role as an independent predictor of 
cardiovascular disease incidence 44,50,59. Considerably less is known about the factors 
that regulate intestinal apoC-III. In this work, we show that intestinal apoC-III expression 
does not change in response to fatty acids, glucose, or insulin administration, in contrast 
to hepatic apoC-III. Intestinal apoC-III is not sensitive to changes in FoxO1 expression 
(which is itself very low in the intestine, as is FoxO1 target IGFBP-1), nor is intestinal 
apoC-III responsive to the western diet, a significant contrast to hepatic apoC-III 
stimulation during feeding with a western diet. These data strongly suggest that 
intestinal apoC-III is not a FoxO1 target. These data support the idea that apoC-III is not 
regulated coordinately with hepatic apoC-III, and establishes another key aspect of 
apoC-III that is unique in the intestine and different from the liver. 
         In these studies, we have focused on dietary lipid and glucose, since these were 
previously identified as major drivers of apoC-III expression in liver 59,77,80. Because we 
have identified a unique consequence of apoC-III overexpression in the intestine (the 
inhibition of dietary fat absorption coupled with altered chylomicron secretion)20,75, and 
because regulation of apoC-III in Caco-2 cell culture is so far removed from in vivo 
conditions that might regulate apoC-III, we wanted to establish the critical dietary factors 
in the regulation of intestinal apoC-III. 
 Dong et al previously established that hepatic apoC-III is a target of FoxO1, 
through the –498/–403 element in the APOC3 promoter 59. They showed that deletion of 
this consensus IRE causes unrestrained apoC-III expression during insulin-resistance 
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and diabetes, leading to hypertriglyceridemia. As part of their assessment of FoxO1 and 
apoC-III, Dong et al also provide evidence from Caco-2 cells overexpressing 
constitutively active FoxO1 that apoC-III expression is also under the control of FoxO1 
in the intestine. They suggest that apoC-III is coordinately regulated in both intestine 
and liver. 
 Instead of Caco-2 cells, here we have used primary murine enteroids, isolated 
and cultured from duodenal and jejunal stem cells. We have previously established that 
these duodenal enteroids absorb fatty acid and form triglyceride-rich chylomicrons, 
which mirrors their origin in the small intestine. This primary culture system significantly 
improves upon Caco-2 cells because of their 3D architecture, with enterocytes arranged 
around a central lumen, and a basolateral surface facing the media. Therefore, the lack 
of apoC-III regulation in response to individual stimuli in this culture system strongly 
supports the idea that intestinal apoC-III, within the in vivo context, is not regulated by 
dietary factors in parallel with the liver.   
 We find that FoxO1 expression in mouse intestine is extremely low, and 
treatment with insulin changes this very slightly. This is in contrast to Dong et al. 
However, our data support recent work by Accili et al. 81, who have established a role of 
FoxO1 in the intestine in endocrine progenitor and serotonin-producing cells. Accili et al. 
use immunohistochemistry for a detailed analysis of FoxO1 expression in the human 
gut. They establish that FoxO1 is enriched in the crypt bottoms, and specifically co-
localizes with serotonin (5HT)-positive endocrine (rather than absorptive enterocyte) 
cells. Our data in intact mouse intestine supports this finding because we see such low 
expression in whole tissue (endocrine cells are vastly outnumbered by enterocytes). 
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 Primary enteroids also maintain a small population of enteroendocrine cells, 
which is likely the source of FoxO1 expression in our cultures. The restriction of FoxO1 
to endocrine cells in the intestine would preclude it from directly regulating apoC-III 
expression in the absorptive epithelium, though this does not necessarily mean that 
endocrine cells don’t play an important role in modulating the enterocyte function. 
Why does it matter that intestinal apoC-III in not regulated by western diet, or through 
the action of FoxO1? Our findings are additional support for the notion that while the 
liver and intestine share the role of triglyceride-rich lipoprotein synthesis and secretion, 
they do not share identical regulatory pathways for proteins that are involved. Our data 
also support the notion that apoC-III secretion from the intestine is under a unique set of 
pressures.  Whereas the liver can quite significantly change VLDL secretion rates in 
response to the presence or absence of substrate and hormones, the intestine is less 
labile in the face of dietary lipid, which is quickly and efficiently secreted in 
chylomicrons. Therefore, our finding that apoC-III levels in the intestine do not change, 
suggests that apoC-III is important for this physiological action of the intestine, and that 
there is still room to identify factors that might inhibit apoC-III in this tissue for the 
purposes of ameliorating its stimulatory role in plasma hypertriglyceridemia and CVD.  
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Summary and Conclusions 
 
 Our work demonstrates that intestinal apoC-III is not regulated in vivo or in vitro 
by glucose, insulin, or fat and is therefore not coordinately regulated with hepatic apoC-
III, which responds to those factors. Furthermore, this study determines that FoxO1 is 
not a regulator of intestinal apoC-III. Our lab has previously demonstrated that the 
physiological function of intestinal apoC-III differs drastically from hepatic apoC-III. 
Hence, both the regulation and role of intestinal apoC-III is distinctive from what we 
know about apoC-III in the liver.  
Future Directions 
  
 Given the importance of the digestive system in mediating the body’s interaction 
with exogenous nutrients, the intestine is likely still an important mediator of CVD risk. 
Since prior research by our lab has demonstrated that the physiological role of apoC-III 
in the intestine differs from that in the liver, it may be possible that intestinal apoC-III can 
favorably alter CVD risk. In the future, an organ-specific knockout of apoC-III will 
delineate the precise role of apoC-III in each tissue. We also have yet to uncover why 
apoC-III decreases TAG secretion from enterocytes and the precise machinery behind 
that effect. And finally, this work does not support the hypothesis that FoxO1 regulates 
apoC3 in the intestine. We did not uncover in this study the factors that regulate 
intestinal apoC-III. Continued exploration of factors that regulate apoC-III expression in 
the intestine are still necessary. 
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